COO of Novocure (30-Year Financial, Insider Trades) Wilhelmus Cm Groenhuysen (insider trades) sold 75,868 shares of NVCR on 09/15/2020 at an average price of $101.53 a share. The total sale was $7.7 million.
NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors. NovoCure Ltd has a market cap of $10.84 billion; its shares were traded at around $107.25 with a P/E ratio of 893.76 and P/S ratio of 27.66.
Directors and Officers Recent Trades:
- Director Gabriel Leung sold 19,565 shares of NVCR stock on 09/15/2020 at the average price of $97.44. The price of the stock has increased by 10.07% since.
- COO Wilhelmus Cm Groenhuysen sold 75,868 shares of NVCR stock on 09/15/2020 at the average price of $101.53. The price of the stock has increased by 5.63% since.
- Director Gabriel Leung sold 19,114 shares of NVCR stock on 09/10/2020 at the average price of $87.8. The price of the stock has increased by 22.15% since.
- Chief Commercial Officer Pritesh Shah sold 28,321 shares of NVCR stock on 09/09/2020 at the average price of $85.41. The price of the stock has increased by 25.57% since.
- Director Gabriel Leung sold 100 shares of NVCR stock on 09/02/2020 at the average price of $85. The price of the stock has increased by 26.18% since.
For the complete insider trading history of NVCR, click here
.
